Overview
Glioma is a type of primary brain or spinal‑cord tumor that originates from glial cells—the supportive cells that surround and nourish neurons. Glial cells include astrocytes, oligodendrocytes, and ependymal cells; when these cells become cancerous, they form a glioma. Gliomas are the most common primary tumors of the central nervous system (CNS), accounting for roughly 30% of all brain tumors and 80% of malignant CNS neoplasms.1
Who it affects: Gliomas can develop at any age, but the incidence rises sharply after age 40. In the United States, about 23,000 new cases are diagnosed each year, with a median age at diagnosis of 55 years.2 Slightly more men than women are affected, and the disease occurs worldwide without major ethnic differences.
Prevalence: Roughly 7–10 per 100,000 people in the U.S. are living with a glioma at any given time. High‑grade (grade III–IV) gliomas, especially glioblastoma multiforme (GBM), have a poorer prognosis, with a 5‑year survival of <10% for GBM compared with up to 70% for low‑grade (grade I–II) tumors when they are completely resected.3
Symptoms
Because gliomas grow within the brain or spinal cord, symptoms reflect the region that is compressed or infiltrated. The onset can be gradual (low‑grade tumors) or rapid (high‑grade). Common signs include:
- Headache: Often worse in the morning or when lying down; caused by increased intracranial pressure.
- Seizures: The first manifestation in up to 40% of patients, especially with cortical involvement.
- Weakness or numbness: Typically affecting one side of the body (hemiparesis) if the motor cortex is involved.
- Speech or language problems: Difficulty finding words, slurred speech, or impaired comprehension when the dominant (usually left) hemisphere is affected.
- Vision changes: Blurred vision, double vision, loss of peripheral vision, or loss of visual fields.
- Balance and coordination issues: Unsteady gait, dizziness, or clumsiness when the cerebellum or brainstem is involved.
- Cognitive or personality changes: Memory loss, confusion, decreased concentration, or altered behavior.
- Hormonal disturbances: When tumors are near the hypothalamus or pituitary gland, they can cause appetite changes, temperature dysregulation, or menstrual irregularities.
- Nausea & vomiting: Often linked to increased intracranial pressure.
- Back pain or radicular pain: In spinal gliomas, pain may radiate along the nerve root distribution.
Symptoms that develop suddenly or worsen rapidly (e.g., sudden severe headache, new seizures, rapid loss of consciousness) require immediate medical attention.
Causes and Risk Factors
Most gliomas arise spontaneously; the exact cause is unknown, but several factors influence risk:
Genetic and Molecular Factors
- Inherited syndromes:
- Neurofibromatosis type 1 (NF1) – increases risk of low‑grade gliomas.
- Neurofibromatosis type 2 (NF2) – associated with ependymomas and meningiomas, but may also predispose to gliomas.
- Li‑Fraumeni syndrome – TP53 mutations raise the likelihood of high‑grade gliomas.
- Somatic mutations: IDH1/IDH2, EGFR amplification, PTEN loss, and MGMT promoter methylation are common in adult gliomas and guide prognosis and therapy.4
Environmental Factors
- Ionizing radiation: Prior therapeutic radiation to the head (e.g., for childhood cancers) modestly raises risk (<2‑3 fold).5
- Occupational exposures: Limited evidence links high‑level exposure to pesticides, solvents, or metal fumes with glioma risk, but data remain inconclusive.
Demographic Factors
- Age – incidence peaks after 40 years.
- Sex – males have a 1.2‑to‑1.5‑fold higher risk.
- Ethnicity – slight variations; Caucasians have marginally higher reported rates, possibly reflecting diagnostic access.
Diagnosis
Accurate diagnosis relies on a combination of clinical evaluation, imaging, and, when safe, tissue sampling.
Initial Clinical Assessment
- Neurological examination to localize deficits.
- Detailed history focusing on symptom onset, seizure activity, and prior radiation exposure.
Imaging Studies
- MRI with contrast (gadolinium): Gold‑standard for brain tumors. Provides information on tumor size, location, edema, and enhancement patterns.
- Advanced MRI techniques: Diffusion‑weighted imaging, MR spectroscopy, and perfusion MRI help differentiate tumor grade and distinguish glioma from other lesions.
- CT scan: Useful for patients who cannot undergo MRI; helps detect calcifications and bone involvement.
- Spine MRI: Required if spinal cord involvement is suspected.
Biopsy and Histopathology
The definitive diagnosis rests on tissue analysis. Options include:
- Image‑guided stereotactic needle biopsy.
- Open surgical resection (when feasible), which can also provide therapeutic debulking.
Pathology follows the WHO 2021 classification, grading tumors from I (least aggressive) to IV (most aggressive, e.g., glioblastoma).
Laboratory and Molecular Testing
- Testing for IDH mutation, 1p/19q co‑deletion, MGMT methylation, and EGFR amplification informs prognosis and treatment choices.
- Baseline blood work (CBC, CMP) before surgery or chemotherapy.
Additional Assessments
- Neuro‑cognitive testing for baseline function.
- Neuro‑ophthalmologic exam if visual pathways are involved.
- Seizure work‑up (EEG) when seizures are a presenting symptom.
Treatment Options
Treatment is individualized based on tumor grade, size, location, patient age, functional status, and molecular profile. A multidisciplinary team (neurosurgeon, neuro‑oncologist, radiation oncologist, neuropathologist, and supportive care specialists) coordinates care.
Surgical Management
- Maximal safe resection: The goal is to remove as much tumor as possible without causing unacceptable neurological deficits. Extent of resection correlates with longer survival, especially for high‑grade gliomas.6
- Image‑guided and fluorescence‑guided surgery: 5‑ALA (gliadel) fluorescence helps surgeons identify tumor margins.
Radiation Therapy
- External beam radiation (EBRT): Standard dose is 60 Gy in 30 fractions for high‑grade gliomas.
- Proton therapy: May reduce dose to surrounding tissue, beneficial for pediatric or eloquent‑area tumors.
- Stereotactic radiosurgery (SRS): Used for small, well‑defined lesions or postoperative boost.
Chemotherapy & Targeted Therapy
- Temozolomide (TMZ): Oral alkylating agent; concurrent with radiation and then adjuvant 6‑12 cycles; standard for newly diagnosed glioblastoma.7
- Bevacizumab: Anti‑VEGF monoclonal antibody; used for recurrent GBM or when edema is severe.
- Targeted agents: Trials of IDH inhibitors (ivosidenib, vorasidenib) for IDH‑mutant tumors; EGFR inhibitors (erlotinib, osimertinib) under investigation.
- Tumor Treating Fields (TTFields): Low‑intensity alternating electric fields applied via transducer arrays; improves survival when combined with temozolomide.
Supportive & Symptomatic Care
- Anticonvulsants: Levetiracetam is first‑line for seizure prophylaxis/management.
- Corticosteroids (dexamethasone): Reduce peritumoral edema and alleviate headaches or focal deficits.
- Physical, occupational, and speech therapy: Critical for regaining function after surgery or during disease progression.
- Psychosocial support: Counseling, support groups, and psychiatric care to address depression, anxiety, and caregiver stress.
Lifestyle and Adjunctive Measures
- Maintain a balanced diet rich in fruits, vegetables, lean protein, and omega‑3 fatty acids; some studies suggest modest benefits for brain health.
- Regular low‑impact exercise (e.g., walking, swimming) improves fatigue and mood, provided neurologic safety is confirmed.
- Avoid tobacco and limit alcohol; both can impair healing and increase infection risk after surgery.
Living with Nervous System Tumor (Glioma)
Living with a glioma involves managing physical symptoms, emotional health, and practical daily concerns.
Daily Management Tips
- Medication adherence: Use a pill organizer or smartphone reminders for temozolomide, steroids, antiepileptics, and any supportive drugs.
- Monitor neurologic changes: Keep a log of new headaches, weakness, vision changes, or seizure activity; report promptly to your care team.
- Energy conservation: Plan rest periods; break tasks into smaller steps; prioritize essential activities.
- Safe driving: Discuss with your neurologist; seizures or visual field loss may require restriction.
- Vaccinations: Stay up‑to‑date with flu and COVID‑19 vaccines; immunosuppression from chemotherapy can increase infection risk.
- Nutrition: Small, frequent meals if nausea is present; consider a nutritionist for high‑calorie, high‑protein snacks.
- Assistive devices: Use walkers, canes, or adaptive kitchen tools as needed.
- Advance care planning: Discuss goals of care, preferences for life‑sustaining treatment, and designate a health proxy early.
Emotional & Social Support
- Join glioma‑specific support groups (online or in‑person).
- Seek counseling from a mental health professional experienced in chronic illness.
- Engage family and friends in caregiving tasks; consider respite services to avoid caregiver burnout.
Follow‑up Care
- Regular MRI scans (every 2‑3 months for high‑grade, every 6‑12 months for low‑grade) to monitor tumor status.
- Scheduled visits with neuro‑oncology to evaluate treatment side effects and adjust therapy.
- Routine labs to check blood counts and liver/kidney function during chemotherapy.
Prevention
Because most gliomas are not preventable, strategies focus on reducing modifiable risk factors and early detection in high‑risk groups.
- Avoid unnecessary head radiation: Discuss risks with physicians when considering diagnostic imaging or therapeutic radiation.
- Protect against ionizing radiation: Use lead shielding during necessary X‑ray or CT studies.
- Healthy lifestyle: Maintain weight, exercise, and avoid smoking; these habits support overall brain health.
- Genetic counseling: Individuals with familial cancer syndromes (NF1, NF2, Li‑Fraumeni) should receive counseling and appropriate surveillance MRI.
- Occupational safety: Use personal protective equipment when handling chemicals or solvents known to be neurotoxic.
Complications
If left untreated or inadequately controlled, gliomas can lead to serious complications:
- Increased intracranial pressure (ICP): Causes persistent headache, vomiting, papilledema, and can lead to brain herniation.
- Recurrent seizures: May become refractory, requiring multiple antiepileptic drugs.
- Neurological deficits: Progressive weakness, aphasia, visual loss, or gait instability.
- Cognitive decline: Memory impairment, reduced executive function, and personality changes.
- Hydrocephalus: Obstructive blockage of CSF pathways, requiring shunt placement.
- Therapy‑related toxicities: Bone‑marrow suppression, infection, radiation necrosis, or steroid‑induced hyperglycemia.
- Secondary malignancies: Particularly after cranial radiation, there is a small risk of developing other CNS or systemic cancers.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe headache unlike any you have had before (often described as “the worst headache of my life”).
- New onset of seizures, especially if they last longer than 5 minutes or occur back‑to‑back (status epilepticus).
- Rapid loss of consciousness, confusion, or difficulty speaking.
- Sudden weakness or numbness on one side of the body, facial droop, or difficulty walking.
- Vomiting repeatedly with a headache or signs of increased intracranial pressure (e.g., blurred vision, papilledema).
- Severe, worsening nausea and vomiting that does not improve with medication.
- Sudden vision loss or double vision.
These signs may indicate acute brain swelling, hemorrhage within the tumor, or a seizure emergency that require prompt evaluation.
Sources:
- Mayo Clinic. “Brain Tumors – Types.” Accessed May 2024.
- National Cancer Institute. “Glioma Statistics.” SEER 2023.
- American Brain Tumor Association. “Glioblastoma Survival Statistics.” 2023 Report.
- World Health Organization. “WHO Classification of Tumours of the Central Nervous System, 5th Edition.” 2021.
- Centers for Disease Control and Prevention. “Radiation and Cancer.” 2022.
- Stupp R, et al. “Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma.” NEJM. 2005;352:987‑996.
- Stupp R, et al. “Effect of Temozolomide on Survival in Glioblastoma.” Clinical Cancer Research. 2019.